SIS 103 SBC
Alternative Names: SIS-103-SBCLatest Information Update: 03 Mar 2023
At a glance
- Originator SiSaf
- Class Antineoplastics; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bone cancer
Most Recent Events
- 13 Jan 2023 Preclinical trials in Bone cancer in United Kingdom (Parenteral) (Sisaf pipeline, January 2023)